Sonnet biotherapeutics announces publication demonstrating suitability of son-1210, the first albumin-binding bifunctional il-12/il-15 fusion protein, for solid tumor immunotherapy

Princeton, nj / accesswire / december 21, 2023 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on son-1210 in frontiers in immunology. son-1210, sonnet's lead proprietary bifunctional compound, combines the company's fhab construct with a novel single-chain il-12 and fully human interleukin 15 (il-15).
SONN Ratings Summary
SONN Quant Ranking